

Electronic Supplementary Information

Click-on Fluorescent Triazolyl Coumarin Peptidomimetics as Inhibitors of Human Breast Cancer Cell line MCF-7

P. Thasnim^a and D. Bahulayan^{a*}

^a Department of Chemistry, University of Calicut, Malappuram 673635, Kerala, India

* Corresponding author. E-mail: bahulayan@yahoo.com

Journal: New Journal of Chemistry

[1] Page 2- 6: Experimental Section

[2] Page 7-25: Mass Spectra of the compounds (**BMU**, **4-AMU**, **1-10**, and **TC1-4 & ATC1-6**).

[3] Page 26-47: FT-IR Spectra of the compounds (**BMU**, **4-AMU**, **1-10**, and **TC1-4 & ATC1-6**).

[4] Page 48-64: ¹H NMR Spectra of the compounds (**BMU**, **4-AMU**, **4**, **5-10**, **TC1-3**, and **ATC1-5**).

[5] Page 65-72: ¹³C NMR Spectra of the compounds (**4-AMU**, **4**, **5-8**, **TC1**, and **ATC4**).

[6] Page 73: Table S1

[7] Page 74-75: **Cytotoxicity evaluation results of TC1 against Human Breast Cancer Cell line MCF-7**

[1] Experimental Section

Procedure for the synthesis of 4-Bromomethyl umbeliferone BMU: Placed a solution of 4-methylumbeliferone (176 mg, 10 mmol) in 20 ml glacial acetic acid in a 500 ml flask. 1.598 g (0.4982 ml, 10 mmol) of bromine in 10 ml glacial acetic acid was added to the flask very slowly (about 30 minutes) from a dropping funnel. The mixture was stirred vigorously during the addition of bromine and kept the temperature at 0-5°C. When the addition was completed, it was allowed to stand at room temperature for 30 minutes. Then the mixture was poured into 400 ml water and stirred well. The precipitate was filtered with suction, washed with cold water. Recrystallised from dilute ethanol to afford reasonably pure **BMU** (white powder). 4-(bromomethyl)-7-hydroxy-2H-chromen-2-one. FT-IR (KBr) $\nu_{\max}$; 1698, 1620, 1600, 1548, 1511, 1441, 1375, 1352, 1263, 1232, 1204, 1141, 1075, 1000, 945, 848, 836, 814, 750, 739, 725, 692, 633, 618, 556, 516, 499, 492, 471, 458, 453, 444, 434, 429, 421, 413, 406, 401 cm^{-1} ; $^1\text{H-NMR}$: 2.490 (s, 2H), 6.972-6.994 (d, 2H), 7.682-7.703 (d, 2H), 8.232 (s, 1H) ppm; HRMS (EI) calcd for $\text{C}_{10}\text{H}_7\text{BrO}_3$ $[\text{M}+\text{H}]^+$: 254.9579, found: $[\text{M}+\text{H}]^+$: 255.0365.

Procedure for the synthesis of 4-Azidomethyl umbeliferone AMU: 4-Bromomethyl umbeliferone (254 mg, 1 mmol), K_2CO_3 (414 mg, 3 mmol) and sodium azide (65 mg, 1 mmol) were stirred at room temperature in DMF. After completion of the reaction, the reaction mixture was poured into ice cold water. The solid product was filtered and dried under vacuum to afford the **4-AMU** in pure form (Brown powder).

4-(azidomethyl)-7-hydroxy-2H-chromen-2-one. FT-IR (KBr) $\nu_{\max}$; 3392, 2920, 2851, 2122, 1701, 1608, 1550, 1507, 1445, 1377, 1340, 1315, 1261, 1201, 1161, 1146, 1105, 810, 754, 725, 631, 580, 552, 529, 456 cm^{-1} ; $^1\text{H-NMR}$: 2.142 (2, 2H), 6.669 (s, 1H), 6.732-6.762 (d, 1H), 6.820-6.841 (d, 1H), 7.361-7.383 (d, 1H), 7.668-7.690 (d, 1H), 8.229 (s, 1H) ppm; $^{13}\text{C NMR}$ (100 MHz, $\text{DMSO}-d_6$): δ 167.01, 163.01, 156.67, 154.65, 129.31, 127.95, 125.01, 113.65, 112.75, 102.13, 56.30, 40.12, 39.91, 39.70, 39.08, 38.07 ppm; HRMS (EI) calcd for $\text{C}_{10}\text{H}_7\text{N}_3\text{O}_3$ $[\text{M}]^+$: 217.0487, found: $[\text{M}]^+$: 217.0118.

General procedure for the synthesis of type 1 alkynes 1-3: Hydroxycoumarin (1mmol), K₂CO₃ (414 mg, 3 mmol) in DMF were heated to 50 °C for half an hour. After cooling, propargyl bromide (0.119 ml, 1 mmol) was added and stirred for 4 hours. The resulting solution is poured into ice water. The precipitate formed was filtered and washed with water to afford pure propargylated coumarin.

Procedure for the synthesis of type 1 alkyne 4: A solution of Coumarin-3-carboxylic acid (1.9 g, 0.01 mol), Propargyl alcohol (0.56 ml, 0.01 mol), N,N-dicyclohexyl carbodiimide (2.3 g, 0.011 mol), and 4-dimethylaminopyridine (0.122 g, 0.001 mol) in dichloromethane was stirred at room temperature for 6 h. After 6 h, the precipitated N,N-dicyclohexylurea was filtered off and the filtrate was washed with water, 5% acetic acid, and again with water. It was then dried over magnesium sulphate and the solvent was evaporated. The residue obtained was washed with petroleum ether to afford the ester prop-2-yn-1-yl 2-oxo-2Hchromene-3-carboxylate (2.4 g, 96%).

General procedure for the synthesis of type 2 alkynes 5-10: A round bottom flask is charged with propargyl derivative of hydroxy benzaldehyde (2 mmol), ketone (2 mmol), acetyl chloride (2 mL), acetonitrile (1 mL) and catalytic amount of BF₃.Et₂O and kept under stirring for 3h at room temperature. The progress of the reaction was monitored by TLC analysis at regular intervals. After 3h, the mixture was quenched with cold water. The solid residue separated was collected and purified by passing it through a silica gel column. Elution of the column with petroleum ether (60-80 °C) / ethyl acetate (9: 1 v/v) afforded **5-10**.

General procedure for the Cu (I) 1, 3-dipolar cycloaddition reactions to synthesis TC1-4 & ATC1-6: An equimolar amount of 4-Azidomethyl umbeliferone **4-AMU** (1 mmol) and the alkynes **1-10** (1 mmol) are dissolved in minimum amount of DMSO. To this, 2 ml of *t*-BuOH, 1 ml of water, CuSO₄·5H₂O (200 mg) and sodium ascorbate (150 mg) are added and stirred at room temperature for 12 h, and then poured in to cold water. The precipitated click product was filtered, washed with water and dried under vacuum to afford **TC1-4 & ATC1-6** in pure form.

1. 7-hydroxy-4-((4-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)-2H-chromen-2-one (**TC1**- white powder). FT-IR, KBr, $\nu_{\max}$: 3439,2922,2852,1715,1619,1572,1509,1467,1389,1349,1326,1295,1225,1206,1151,1063,1019,984,941, 844, 822,765,686 cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6): δ 2.297-2.321 (d, 3H), 4.022-4.070 (q, 2H), 5.023 (s, 1H), 5.464-5.468 (d, 2H), 5.998 (s, 2H), 6.165 (s, 1H), 7.314-7.438 (m, 3H), 7.554 (s, 1H), 7.570-8.0121 (m, 4H) ppm; HRMS (EI) calcd for $\text{C}_{23}\text{H}_{17}\text{N}_3\text{O}_6$ $[\text{M}+\text{H}]^+$: 432.1117 , found: $[\text{M}+\text{H}]^+$: 432.1188.

2. 7-hydroxy-4-((4-(((4-methyl-2-oxo-2H-chromen-7-yl) oxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)-2H-chromen-2-one (**TC2**- white powder). FT-IR, KBr, $\nu_{\max}$: 3422,3165,2923,2853,1726,1685,1615,1573,1557,1508,1466,1402,1354,1322,1283,1228,1159, 1135, 1089,1045,1016,949,906,836,802,765,703,656,620,566,534,507,458 cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6): δ 4.693-4.622 (q, 1H), 5.238 (s, 2H), 5.559 (s, 1H), 6.502-6.691 (q, 1H), 6.864-6.876 (d, 1H), 7.090-7.354 (m, 8H), 7.963 (s, 1H) ppm; HRMS (EI) calcd for $\text{C}_{23}\text{H}_{17}\text{N}_3\text{O}_6$ $[\text{M}+\text{H}]^+$: 418.0961 , found: $[\text{M}+\text{H}]^+$: 418.1016.

3. 7-hydroxy-4-((4-(((2-oxo-2H-chromen-4-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)-2H-chromen-2-one (**TC3**- white powder). FT-IR, KBr, $\nu_{\max}$: 3421,2919,2850,1728,1710,1610,1563,1509,1493,1449,1425,1387,1354,1332,1273,1244, 1197,1156, 1128,1107, 1085,1047,947,882,764,747,655 cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6): δ 4.2660-4.3096 (q, 2H), 5.3050 (s, 1H), 5.7121-5.7860 (d, 3H), 6.3132 (s, 2H), 6.7602-6.7765 (d, 2H), 7.3075-7.4262 (m, 5H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6): δ 168.20,160.80,160.27,156.05,141.43,135.53,135.07,131.75,130.04,127.80,127.47,127.27,114.52,114.33,87.47,66.48,60.66,48.33,45.33,40.12,39.31,33.24,33.07,30.87,30.66 ppm; HRMS (EI) calcd for $\text{C}_{22}\text{H}_{15}\text{N}_3\text{O}_6$ $[\text{M}+\text{H}]^+$: 418.0961 , found: $[\text{M}+\text{H}]^+$: 418.1029.

4. (1-((7-hydroxy-2-oxo-2H-chromen-4-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl 2-oxo-2H-chromene-3-carboxylate (**TC4**- white powder). FT-IR, KBr, $\nu_{\max}$: 3431,2925,2852,1717,1693,1648,1617,1576,1555,1456,1401,1369,1289,1258,1233,1181,1033,923,882, 779,759,644,595,464,418 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{23}\text{H}_{15}\text{N}_3\text{O}_7[\text{M}+\text{H}]^+$: 446.0910 , found: $[\text{M}+\text{H}]^+$: 446.1774.

5. N-(1-(4-((1-((7-hydroxy-2-oxo-2H-chromen-4-yl)methyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3-oxo-3-phenylpropyl)acetamide (**ATC1**- white powder). FT-IR, KBr, $\nu_{\max}$: 3414,2923,2851,1725,1648,1589,1489,1455,1400,1376,1292,1240,1121,1091,1024,818, 754,620,529,470,418 cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6): δ 1.517 (s, 3H), 3.271-3.278 (d, 1H), 3.296-3.313 (d, 1H), 4.617-4.653 (q, 2H), 5.229 (s, 1H), 5.485-5.564 (d, 3H), 6.576-6.617 (q, 1H), 6.870 (s, 1H), 7.087-7.368 (m, 11H), 7.998 (s, 1H), 8.248 (s, 1H) ppm; HRMS (EI) calcd for $\text{C}_{30}\text{H}_{26}\text{N}_4\text{O}_6[\text{M}+\text{H}]^+$: 539.1852 , found: $[\text{M}+\text{H}]^+$: 539.2055.

6. N-(3-(4-bromophenyl)-1-(4-((1-((7-hydroxy-2-oxo-2H-chromen-4-yl)methyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3-oxopropyl)acetamide (**ATC2**- white powder). FT-IR, KBr, $\nu_{\max}$: 3420,2922,1731,1648,1600,1556,1490,1450,1375,1358,1320, 1240,1160,1122,1088,1016,949,817,754,691,504 cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6): δ 1.502 (s, 3H), 2.297-2.321 (d, 2H), 4.014-4.074 (m, 2H), 5.023 (s, 2H), 5.468-5.613 (t, 1H), 6.147 (s, 1H), 7.299-8.121 (m, 13 H), 10.074 (s, 1H) ppm; HRMS (EI) calcd for $\text{C}_{30}\text{H}_{25}\text{BrN}_4\text{O}_6[\text{M}+\text{H}]^+$: 617.0957 , found: $[\text{M}+\text{H}]^+$: 617.1911.


7. N-(1-(2-((1-((7-hydroxy-2-oxo-2H-chromen-4-yl)methyl)-1H-1,2,3-triazol-4-yl)methoxy) phenyl)-3-oxo-3-phenylpropyl)acetamide (**ATC3**- white powder). FT-IR, KBr, $\nu_{\max}$: 3423,2922,2852,1728,1655,1599,1508,1466,1419,1383,1323,1248,1171,1125, 1088, 1019,832,763,725,550,502,466 cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6): δ 1.772 (s, 3H), 2.791-2.864 (d, 2H), 4.759-4.794 (d, 2H), 4.836-4.864 (d, 1H), 5.875 (s, 1H), 5.891 (s, 1H), 7.225-7.313 (m, 6H), 7.706-7.930 (m, 9H), 10.059 (s, 1H) ppm; HRMS (EI) calcd for $\text{C}_{30}\text{H}_{26}\text{N}_4\text{O}_6[\text{M}+\text{H}]^+$: 539.1852 , found: $[\text{M}+\text{H}]^+$: 539.1747.


8. N-(3-(4-chlorophenyl)-1-(2-((1-((7-hydroxy-2-oxo-2H-chromen-4-yl)methyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3-oxopropyl)acetamide (**ATC4**- white powder). FT-IR, KBr, $\nu_{\max}$: 3385,2983,1700,1647,1579,1591,1445,1351,1301, 1223,1097, 1040,923,808,759,735,689,458,421, cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6): δ 1.6795-1.7685 (m, 3H), 2.4337-2.5221 (t, 2H), 4.4094-4.4133 (d, 2H), 5.2202 (s, 1H), 5.3973 (s, 1H), 5.4245 (s, 1H), 6.6648-6.9757 (m, 10 H), 7.3284-7.5221 (m, 2H), 7.9360 (s, 1H), 8.3214 (s, 1H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6): δ 194.01,194.00,168.43,168.73,161.04,142.20,132.62,130.31,129.92, 129.83,127.62,127.74,122.22,114.74,76.68,55.68,48.73,48.01,39.70,39.50,39.07,34.06,22.52ppm;HRMS (EI) calcd for $\text{C}_{30}\text{H}_{25}\text{ClN}_4\text{O}_6$ $[\text{M}]^+$: 572.1463 , found: $[\text{M}]^+$: 572.1482.


9. N-(3-(4-chlorophenyl)-1-(4-((1-((7-hydroxy-2-oxo-2H-chromen-4-yl)methyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3-oxopropyl)acetamide (**ATC5**- white powder). FT-IR, KBr, $\nu_{\max}$: 3433,2923,1787,1765,1650,1596,1557, 1529,1500,1449,1421, 1349,1325,1272,1230,1158,1000,886,860,809,776,700,623,542 cm^{-1} ; ^1H NMR (400 MHz, DMSO- d_6): δ 1.6057 (s, 3H), 3.3075-3.2340 (d, 2H), 4.2811- 4.2951 (d, 2H), 5.1848 (s, 1H), 5.3050-5.3096 (d, 2H), 5.5231 (s, 1H), 6.7602-6.7765 (d, 1H), 7.2837-7.3146 (m, 6H), 7.4336-7.6278 (m, 10 H), 8.5555 (s, 1H) ppm;HRMS (EI) calcd for $\text{C}_{30}\text{H}_{25}\text{ClN}_4\text{O}_6$ $[\text{M}+\text{H}]^+$: 573.1463 , found: $[\text{M}+\text{H}]^+$: 573.1219.


10. N-(1-(2-bromophenyl)-3-(4-((1-((7-hydroxy-2-oxo-2H-chromen-4-yl)methyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-3-oxopropyl)acetamide (**ATC6**- white powder). FT-IR, KBr, $\nu_{\max}$: 3410,2923,1757,1687,1490,1446,1408,1359,1325,1272,1230, 1180,1157,1091,1014,952,833,754,727,616,585,508,486 cm^{-1} ;HRMS (EI) calcd for $\text{C}_{30}\text{H}_{25}\text{BrN}_4\text{O}_6$ $[\text{M}+\text{H}]^+$: 617.0957 , found: $[\text{M}+\text{H}]^+$: 617.0110.

[2] Mass Spectra of compounds












6










9


MS Spectrum

*MSD1 SPC, time=0.340 of D:\DATA\APR11\15042011 2011-04-15 14-41-37\1104140014.D MM-APCI, Pos, Scan, Frag: 90


Max: 529408










TC2




TC3










ATC2









ATC5




ATC6





[3] Infrared Spectra of compounds





4-AMU















5













9










TC2













ATC2




ATC4








[4] ^1H NMR spectra of compounds





4-AMU

SAIFNM170508A-02(B)

SAIF Cochin




4




PULSE SEQUENCE	OBSERVE	H1, 399.2769826	DATA PROCESSING	Solvent: DMSO	SAMPLE: PF12G
Relax: 30.00 sec			Line broadening 0.2 Hz	Temp: 25.0 C / 238.1 K	
Pulse: 45.0 degrees			FI size 65536	Sample #26, Operator: valkup	
Acq. time 2.536 sec				File: PF12G_01	
Width 6410.3 Hz				VMRS-608 "400MHz"	
16 repetitions					
Total time 1 minute					

File: /home/valkup/vmrsys/data/PP12G01a16a.d1c /home/valkup/vmrsys/data/auto_2016.65.01




6



Chemical structure: CC(=O)C(Oc1ccccc1)C#C

¹H NMR spectrum (CDCl₃) showing peaks and integration values:

Chemical Shift (ppm)	Integration
7.670, 7.661, 7.648, 7.625, 7.615	1.00
7.518, 7.319, 7.301, 7.259, 7.255, 7.238, 7.211, 7.215, 7.075, 7.055, 6.985, 6.987, 6.949	2.14
5.861, 4.825	2.14
3.660, 3.651, 3.650, 3.462, 3.432, 3.425, 3.393, 3.312, 3.282, 3.215, 3.180, 3.175, 3.150, 2.599, 2.590, 2.493	0.97
2.145, 2.141, 2.135, 2.131, 2.125, 2.121, 2.115, 2.111, 2.105, 2.101, 2.095	1.34
1.895, 1.815, 1.781	8.24



PULSE SEQUENCE Relax 1.000 sec Pulse 45.0 degrees Acq. time 2.049 sec Width 6010.3 Hz 32 repetitions Total time 1 minutes	OBSERVE H1, 399.2691587	DATA PROCESSING Resol 0.4 enhancement -0.0 Hz FT size 65536	Solvent: dmsc Temp 29.9 C / 258.1 K Sample #38, Operator: walkup File: An-11_01 VNMR5-000 "400MR"	SAMPLE: An-11
File: /home/walkup/vnmrsys/data/nn/Auto_2011.04.09_01				

¹H NMR spectrum of compound 10 in CDCl₃.


Chemical structure of compound 10: CC(=O)N[C@@H](c1ccccc1OC#CC(=O)Cc2ccc(Cl)cc2)c3ccccc3


Peak list (ppm): 8.789, 8.780, 8.710, 8.610, 8.005, 7.885, 7.880, 7.811, 7.603, 7.588, 7.585, 7.585, 7.502, 7.241, 7.232, 7.227, 7.222, 7.215, 7.057, 6.986, 6.983, 6.951, 6.948, 4.871, 4.669, 3.634, 3.628, 3.614, 3.612, 3.577, 3.581, 3.580, 3.577, 3.576, 3.566, 3.555, 3.553, 3.551, 3.551, 3.550, 3.548, 3.528, 3.525, 3.516, 3.189, 3.174, 3.173, 3.133, 2.576, 2.569, 2.555, 2.550, 2.486, 2.480, 2.082, 1.789.

Integration values: 1.06, 1.89, 1.83, 1.01, 0.94, 1.00, 1.00, 1.99, 1.98, 0.75, 1.16, 2.96.

PULSE SEQUENCE	OBSERVE H1, 399.2691597	DATA PROCESSING	Solvent: dmso	SAMPLE: An-12
Relax delay 1.000 sec		Decoupling: enhancement -0.0 Hz	Temp: 25.0 C / 286.1 K	
Pulse 45.0 degrees		FT size 65536	Sample #37 Operator: walkup	
Acq. time 2.048 sec			File: An-12_01	
Width 9410.3 Hz			VNMR5-400 "400MHz"	
32 repetitions				
Total time 1 minutes				
File: /home/walkup/vnmrsvs/data/h1auto/bin/fir: /home/walkup/vnmrsvs/data/auto.2011.04.09_01				

9







TC1

PROTON CDCl3 {C:\Bruker\TopSpin3.2} nmr 27

8.121
8.087
8.070
8.054
7.938
7.922
7.621
7.687
7.570
7.554
7.438
7.422
7.433
7.314
6.165
5.998
5.468
5.464
5.023
4.070
4.054
4.038
4.022
2.321
2.297




Current Data Parameters
NAME Soumya
EXPNO 6
PROCNO 1

F2 - Acquisition Parameters
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 10000.000 Hz
FIDRES 0.152588 Hz
AQ 3.2767999 sec
RG 181
DW 50.000 usec
DE 6.50 usec
TE 301.0 K
D1 1.00000000 sec
TD0 1

----- CHANNEL f1 -----
SFO1 500.2330891 MHz
NUC1 1H
P1 9.04 usec
PLW1 27.16399956 W

F2 - Processing parameters
SI 65536
SF 500.2300475 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00

TC2



```


Current Data Parameters
NAME          Soumya
EXPNO         1
PROCNO        1


F2 - Acquisition Parameters
INSTRUM       spect
PROBHD        5 mm PABBO BB-
PULPROG       zg30
TD            65536
SOLVENT       CDCl3
NS            16
DS            2
SWH           10000.000 Hz
FIDRES        0.152588 Hz
AQ            3.2767999 sec
RG            203
DW            50.000 usec
DE            6.50 usec
TE            298.9 K
D1            1.00000000 sec
TD0           1

----- CHANNEL f1 -----
SFO1          500.2330891 MHz
NUC1           1H
P1             9.04 usec
PLW1          27.16399956 W

F2 - Processing parameters
SI            65536
SF            500.2300597 MHz
WDW           EM
SSB           0
LB            0.30 Hz
GB            0
PC            1.00
  
```

TC3





Chemical structure of **1** is shown above the spectrum. The spectrum displays peaks corresponding to the structure, with chemical shifts (ppm) and integrations (area) indicated below the baseline.

Chemical shifts (ppm): 10.074, 8.121, 8.087, 8.070, 8.054, 7.938, 7.922, 7.627, 7.612, 7.574, 7.559, 7.465, 7.449, 7.433, 7.314, 7.299, 6.147, 5.613, 5.598, 5.468, 5.464, 5.023, 4.074, 4.059, 4.065, 4.049, 4.033, 4.014, 2.321, 2.297, 1.502.

Integrations (area): 0.99, 2.16, 2.35, 1.00, 2.30, 1.10, 2.42, 2.06, 0.91, 1.02, 1.74, 0.91, 2.35, 2.27, 3.36.

```

Current Data Parameters
NAME                      Soumya
EXPNO                     6
PROCNO                   1


F2 - Acquisition Parameters
INSTRUM                  spect
PROBHD                   5 mm PABBO BB-
PULPROG                  zg30
TD                        65536
SOLVENT                  CDC13
NS                        16
DS                        2
SWH                      10000.000 Hz
FIDRES                   0.152588 Hz
AQ                       3.2767999 sec
RG                        181
DW                       50.000 usec
DE                       6.50 usec
TE                       301.0 K
D1                       1.00000000 sec
TD0                      1

----- CHANNEL f1 -----
SFO1                    500.2330891 MHz
NUC1                     1H
P1                       9.04 usec
PL1                     27.16399956 W


F2 - Processing parameters
SI                       65536
SF                       500.2300475 MHz
WDW                      EM
SSB                      0
LB                       0.30 Hz
GB                       0
PC                       1.00

```

ATC3



ATC4




Current Data Parameters
 NAME Soumya
 EXPNO 2
 PROCNO 1

F2 - Acquisition Parameters
 INSTRUM spect
 PROBHD 5 mm PABBO BB-
 PULPROG zg30
 TD 65536
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 10000.000 Hz
 FIDRES 0.152588 Hz
 AQ 3.2767999 sec
 RG 144
 DW 50.000 usec
 DE 6.50 usec
 TR 298.0 K
 D1 1.00000000 sec
 TDO 1

----- CHANNEL f1 -----
 SFO1 500.2330891 MHz
 NUC1 1H
 P1 9.04 usec
 PLW1 27.16399956 W

F2 - Processing parameters
 SI 65536
 SF 500.2300453 MHz
 WDW RM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

ATC5




Current Data Parameters
NAME Soumya
EXPNO 4
PROCNO 1

F2 - Acquisition Parameters
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 10000.000 Hz
FIDRES 0.152588 Hz
AQ 3.2767999 sec
RG 203
LW 50.000 usec
DE 6.50 usec
TE 298.0 K
D1 1.00000000 sec
TD0 1



----- CHANNEL f1 -----
SFO1 500.2330891 MHz
NUC1 1H
P1 9.04 usec
PLW1 27.16399956 W

F2 - Processing parameters
SI 65536
SF 500.2300458 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00

[5] ^{13}C NMR Spectra of compounds




4




PULSE SEQUENCE Relax. delay 2.000 sec Pulse 45.0 degrees Acq. time 1.333 sec Width 24508.6 Hz 2000 repetitions Total time 110 minutes	OBSERVE C13, 160 3963265 RECOUPE H1, 397 2763079 Power 40 dB continuously on WALTZ-16 modulated	DATA PROCESSING Line broadening 1.0 Hz FT size 151872	Solvent: dmsd Temp. 25.0 C / 296.1 K Sample #28, Operator: walkup F101: PP120.02 VNMR-903 "400MR"	SAMPLE: PP120
--	---	--	--	----------------------



File: /home/walkup/vnmr/sys/data/PP120/20100901
Dir: /home/walkup/vnmr/sys/data/2010.09.01

5




6





PULSE SEQUENCE	OBSERVE C13, 100.3363562	DATA PROCESSING	Solvent: dms	SAMPLE: An-12
Relax. delay 1.000 sec	DECOUPLE H1, 399.2711702	Line broadening 0.5 Hz	Temp. 25.0 C / 298.1 K	
Pulse 45.0 degrees	Power on de	FT size 65536	Sample #37, Operator: walkup	
Acq. time 1.360 sec	continuously on		File: An-12_02	
Width 24509.8 Hz	WALTZ-16 modulated		VNMR-100 "400MHz"	
3000 repetitions				
Total time 115 minutes				



File: /home/walkup/vnmrsys/data/Ap4126211702 dir: /home/walkup/vnmrsys/data/auto_2011.04.08_01



PULSE SEQUENCE Relax. delay 1.000 sec Pulse 45.0 degrees Acq. time 1.300 sec Width 20508.8 Hz 3500 repetitions Total time 2.2 hours	OBSERVE C13, 100.3963513 DECOUPLE H1, 399.2711702 Power 40 dB Continuously on WALTZ-16 modulated	DATA PROCESSING Line broadening 0.5 Hz FT size 65536	Solvent: dmsd Temp. 25.0 C / 298.1 K Sample #25, Operator: walkup File: An-68_01 VNMRS-400 "400MHz"	SAMPLE: An-68
--	--	---	---	----------------------

File: /home/walkup/vnmrsys/data/An-68_01.fid dir: /home/walkup/vnmrsys/data/auto_2011.04.20

TC1



ATC4





Table S1 : Drug like properties of click products TC1-4 & ATC1-6

Compound	MW	natoms	TPSA	volume	miLogP	nON	nOHNH	nviolations	nrothb
TC1	431.40	32	120.60	360.17	3.27	9	1	0	5
TC2	417.38	31	120.60	343.61	2.84	9	1	0	5
TC3	417.38	31	120.60	343.61	2.89	9	1	0	5
TC4	445.39	33	137.67	362.59	2.62	10	1	0	6
ATC1	538.56	40	136.56	471.03	2.46	10	2	1	10
ATC2	617.46	41	136.56	488.92	3.27	10	2	1	10
ATC3	538.56	40	136.56	471.03	2.41	10	2	1	10
ATC4	573.00	41	136.56	484.57	3.09	10	2	1	10
ATC5	573.00	41	136.56	484.57	3.14	10	2	1	10
ATC6	597.58	44	182.38	511.17	1.99	13	2	2	12

Cytotoxicity evaluation results of TC1 against Human Breast Cancer Cell line MCF-7

The MCF-7 cells were maintained in RPMI medium 1640 supplemented with 10% fetal bovine serum as well as 100 µg/mL streptomycin, 100 U/mL penicillin, 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L Na bicarbonate, 0.1 mM nonessential amino acids, and 1.0 mM of Na pyruvate in a humidified atmosphere containing 5% CO₂ at 37 °C. The MCF-7 cells in the log phase were seeded in 96-well plates at a concentration of 1.0 x 10⁴ cells/well and incubated overnight at 37 °C in 5%CO₂ humidified environment. The cells were then treated with different concentrations of the **TC1** such as 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 µM/mL (dissolved with RPMI medium 1640), respectively. Controls were also cultivated under same conditions without the addition of **TC1**. The treated cells were incubated for 48 h and then subjected for MTT assay.





Figure S1. MTT assay results confirming the in vitro cytotoxicity effect of **TC1** against the MCF-7 cells. The detected IC₅₀ concentration was 30 µM/mL.

The stock concentration (5 mg/mL) of MTT-(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was prepared and 100 µL of MTT was added in each **TC1** treated wells and incubated for 4h. Purple colour formazan crystals were observed and these crystals were dissolved in 100 µL of dimethyl sulphoxide (DMSO), and read at 620 nm in a multiwell ELISA plate reader (Thermo, Multiskan). The dose dependent cytotoxicity was observed in **TC1** treated MCF-7 cells.³⁰ Fifty percentage of cell death, which determines the inhibitory concentration (IC₅₀) value of **TC1** against MCF-7 cells holds at 30 µM in 48 h (figure S1).

In order to study the morphological changes, MCF-7 cells were grown (1 x 10⁵ cells/cover slip) and incubated with **TC1** at its IC₅₀ concentration (30 µM/mL) and then they were fixed in a mixture of methanol and acetic acid (3:1, v/v). The cover slips were gently mounted on glass slides for the morphometric analysis. Morphological changes of MCF-7 cells were analyzed under a Nikon (Japan) bright field inverted light microscope at 40x magnification. The most recognizable morphological changes of **TC1** treated cells observed in this study were the cytoplasmic condensation, cell shrinkage, production of numerous cell surface protuberances at the plasma membrane blebbing and hyper condensed chromatin as shown in treated MCF-7 cells.



FigureS2. Bright field inverted light microscopy images (a) (Control), (b) (IC25) and (c) (IC50) and fluorescence microscopy images (d) (Control), (e) (IC25) and (f) (IC50) of **TC1** treated MCF-7 cells.

Followed by this, DAPI (4,6-diamidino-2-phenylindole, dihydrochloride) staining was carried out. For this, the MCF-7 cells incubated with **TC1** at its IC50 concentration (30 μ M/mL) for 48 h and then they were fixed in a mixture of methanol and acetic acid (3:1, v/v) prior to washing with PBS. The washed cells were then stained with 1 mg/mL DAPI (4,6-diamidino-2-phenylindole, dihydrochloride) for 20 min. in a dark atmosphere. The stained images were recorded using a fluorescent microscope with appropriate excitation filter. The bright field and fluorescence microscopic images are shown in Figure S2. As shown in figure S2, the strong bluish fluorescence and cellular uptake observed in the imaging studies with **TC1** reveals that these molecules have high potency against breast cancer cell lines (MCF-7).